Review Papers Claim by Claim

Figure A — Recreated: Radius of gyration distributions (glycosylated vs non-glycosylated)

This recreation encodes the paper's central directional observation: glycosylation biases TrkA/TrkB toward more extended Rg distributions compared to their non-glycosylated forms, whereas p75 shows little Rg change across glycosylation states Rg and conformational results

Figure B — Recreated: Contact area contribution of glycans to receptor:neurotrophin interface

Authors report that glycans minimally interact with NT-3 on p75 but significantly contribute to TrkA/TrkB receptor:NT contact area (especially TrkB via Asn338 glycan) — consistent with increased glycan participation in Trk complexes Glycan participation in receptor:NT contacts

Concise critical analysis (visual-first then bullets)

• Reproducibility & data access: The authors deposited initial models, parameter files and trajectory input on Zenodo (DOI available), enabling replication and reuse of their MD systems and analysis pipelines Zenodo data deposit
• Experimental design strengths: multiple biological contexts (dimer+NT, monomer+NT, monomer alone), 3–6 replicas × 500 ns each — adequate sampling strategy for comparative MD across many systems, and consistent analysis (RMSD/RMSF/Rg/PCA/SASA/H-bonds) using standard, modern tools (CHARMM36m, GROMACS, MDAnalysis) MD protocol and analyses
• Key mechanistic claim: Glycans modulate receptor conformational ensembles via steric shielding and by constraining side-chain χ1 distributions at glycosylation Asn residues, promoting extended Trk conformations that preserve neurotrophin access while p75 is stabilized by disulfide ladder and yields minimal glycan effect Mechanistic conclusions from MD
• Major limitations / blindspots (authors acknowledge):
  • Only extracellular domains modeled — no membrane, TM helix, intracellular kinase domains or native membrane microenvironment; membrane proximity and TM interactions can change ECD conformational equilibria (limiting in vivo extrapolation).
  • Glycans were truncated to core (first 5 saccharides, Man3GlcNAc2) for Trks and a modeled complex glycan for p75 — natural glycan heterogeneity, antennary branching, sialylation/fucosylation patterns (which alter charge/sterics) are unrepresented and can change shielding and H-bonding behavior.
  • Finite MD timescales (500 ns replicas) can miss slow-scale rearrangements (µs–ms) and rare events such as full domain reorientations, or cooperative glycan-regulated allostery.
  • Force-field accuracy for glycan–protein interactions is improving, but residual bias remains; hydrogen-bond occupancies and sampling of glycan rotamers depend on parameterization.
  Authors
• Potential confounders not fully explored: cell-type specific glycan heterogeneity (different tissues add different terminal sugars, sialic acid linkages) — authors choose a defensible common core but physiological behavior may differ; also O-glycosylation in p75 linker (not modeled) may modulate flexibility/proteolysis in vivo.
• Suggested immediate follow-ups to strengthen claims:
  1. Simulate representative full-length receptors embedded in a membrane patch with TM helices + ICD segments (coarse-grained for µs sampling, or atomistic with enhanced sampling) to test if membrane anchoring changes ECD bending and glycan shielding.
  2. Run a subset of systems with full, experimentally-informed glycan heterogeneity (sialylated, fucosylated antennae) at key sites (e.g., TrkA Asn358, TrkB Asn338, p75 Asn60) to test how terminal decorations modulate shielding and H-bonds.
  3. Complement MD with experimental biophysical tests: differential protease sensitivity assays +/- glycosidase treatment, BLI/SPR for NT binding kinetics +/- glycosylation mutants, and native-MS or cryo-EM of glycoforms where possible.
• Confidence in central conclusion: Moderate-high that glycosylation materially alters Trk conformational ensembles and shielding (consistent across many simulations and supported by quantitative ASA analyses), but low-moderate regarding exact in vivo functional consequences without membrane, full glycans and experimental validation Confidence/limitations in conclusions

Practical implications & actionable next steps

1. Use the Zenodo deposit to reproduce calculations and re-run SASA/contact analyses with probe radii tuned to specific experimental ligands (e.g., antibody Fv ~25 Å) to assess drug/antibody accessibility Zenodo repository (reanalysis)
2. Design targeted mutants removing single glycans (Asn->Gln at specific sites) combined with experimental binding/activation assays to test whether glycan loss collapses Trk ECDs and reduces NT signaling as predicted.

Minimal, falsifiable statements

- Falsifiable prediction: Removing TrkA Asn358 glycan (modeled shielding of D5) will reduce Rg and produce more bent/compact ECD ensembles and alter NGF binding kinetics; if experiments/extended simulations show no effect, the central mechanistic claim would be refuted Asn358 TrkA shielding claim